Videos

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. A look at clinical trial efficacy data on daratumumab plus bortezomib and venetoclax for multiple myeloma treatment.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Dr. Shaji Kumar reviews data from his BELLINI clinical trial studying venetoclax paired with bortezomib and dexamethasone for multiple myeloma treatment.

Matthew J. Matasar, MD, discusses how updates in the diffuse large B-cell lymphoma field have led to improved quality of life in patients.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Dr. Jonathan Kaufman explains clinical trial data on the efficacy of dexamethasone with venetoclax for multiple myeloma treatment.

Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Shaji Kumar, MD, describes the mechanism of action of BCL-2 inhibitor venetoclax and clinical trial data on its efficacy in multiple myeloma.

Aparna Hegde, MD, discusses the decision to use osimertinib as soon as possible in patients with EGFR-positive non–small cell lung cancer.

Tycel Phillips, MD, discusses the need for more effective agents for treating patients with relapsed/refractory mantle cell lymphoma as alternatives to chimeric antigen receptor T-cell therapy.

Scott Tagawa, MD, MS, FACP wraps up by discussing how he envisions the future of prostate cancer and offers advice to community oncologists treating patients with the disease.

An overview of the barriers and challenges that patients, caregivers, clinicians, and other healthcare personnel may face when radiation-based therapies are used for treatment of prostate cancer.

Scott Tagawa, MD, MS, FACP, discusses other prostate cancer settings besides metastatic CRPC where Lu 177 vipivotide tetraxetan could potentially be useful, and touches on ongoing clinical trials in these settings.

A discussion of key safety data on the VISION trial.

Scott Tagawa, MD, MS, FACP, compares the use of single-agent regimens versus combination regimens in the treatment of metastatic prostate cancer.

Scott Tagawa, MD, MS, FACP, reviews key efficacy data from the VISION trial of Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (CRPC).

A comprehensive review of treatment options for metastatic prostate cancer, including PSMA-targeted therapies.

Scott Tagawa, MD, MS, FACP expands upon prostate-specific membrane antigen (PSMA)-based PET imaging modalities.

A focused discussion on how phenotypic biomarkers and positron emission tomography (PET)-based imaging can be combined to diagnose and treat prostate cancer.

Scott Tagawa, MD, MS, FACP reviews emerging phenotypic biomarker approaches that may complement genomic biomarker testing.

An overview of genomic biomarker testing approaches for patients with prostate cancer.

Scott Tagawa, MD, MS, FACP, comments on some of the clinical factors that impact diagnosis, prognosis, and treatment of prostate cancer.

Danny Nguyen, MD, discusses next steps for research of mobocertinib in patients with EGFR-positive non–small cell lung cancer.

Shaji Kumar, MD, discusses the current treatment options and unmet needs for patients with newly diagnosed multiple myeloma.

Paul G. Richardson, MD, discusses the latest regulatory movement in the multiple myeloma space.

Solange Peters, MD, PhD, discusses the biomarkers for immunotherapy used in the phase 3 CheckMate 743 trial.

Adam Cohen, MD, discusses his presentation on updates in BCMA-directed therapies for multiple myeloma, which he gave during the 3rd Summit of the Americas on Immunotherapies for Hematologic Malignancies.

Guenther Koehne, MD, PhD, discusses the exciting presentations going on at the 3rd Summit of the Americas on Immunotherapies for Hematologic Malignancies.

Pashna Munshi, MD, wraps up by talking about future directions and emerging treatment regimens in the field of GVHD.

A commentary on the patient’s case and strategies for treatment selection and management for those with steroid-refractory disease.

Pashna Munshi, MD, provides an overview of adverse event data from the REACH3 trial of ruxolitinib in patients with steroid-refractory cGVHD and discusses management of patients’ side effects in clinical practice.

A comprehensive review of recent real-world ruxolitinib efficacy data and the use of emerging prognostic markers to risk-stratify patients with cGVHD.

Pashna Munshi, MD, expands upon ruxolitinib’s mechanism of action in steroid-refractory cGVHD and discusses REACH3 efficacy data.